Pediatrix Medical Group (NYSE:MD) Price Target Raised to $15.00

Pediatrix Medical Group (NYSE:MD) had its price target lifted by Mizuho from $13.00 to $15.00 in a research note published on Monday, Benzinga reports. Mizuho currently has a neutral rating on the stock.

A number of other research analysts have also recently commented on MD. Jefferies Financial Group raised Pediatrix Medical Group from a “hold” rating to a “buy” rating and increased their target price for the company from $8.00 to $14.00 in a research note on Thursday, September 26th. StockNews.com upgraded Pediatrix Medical Group from a “sell” rating to a “hold” rating in a research report on Wednesday, August 7th. UBS Group boosted their target price on Pediatrix Medical Group from $9.00 to $10.50 and gave the stock a “neutral” rating in a research report on Friday, August 9th. Finally, Truist Financial increased their price target on shares of Pediatrix Medical Group from $10.00 to $13.00 and gave the company a “hold” rating in a research report on Monday, October 7th. Five equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat, Pediatrix Medical Group presently has an average rating of “Hold” and a consensus price target of $16.10.

Pediatrix Medical Group Price Performance

Shares of NYSE MD opened at $16.06 on Monday. The stock’s 50-day simple moving average is $11.89 and its two-hundred day simple moving average is $9.54. Pediatrix Medical Group has a twelve month low of $6.62 and a twelve month high of $16.41. The firm has a market capitalization of $1.38 billion, a P/E ratio of -5.25, a P/E/G ratio of 2.35 and a beta of 1.55. The company has a quick ratio of 1.38, a current ratio of 1.42 and a debt-to-equity ratio of 0.83.

Pediatrix Medical Group (NYSE:MD) last posted its quarterly earnings data on Friday, November 1st. The company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.07. The company had revenue of $511.20 million for the quarter, compared to analysts’ expectations of $498.87 million. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. Pediatrix Medical Group’s revenue for the quarter was up .9% compared to the same quarter last year. During the same period in the prior year, the business earned $0.29 earnings per share. As a group, equities analysts anticipate that Pediatrix Medical Group will post 1.19 EPS for the current fiscal year.

Insider Buying and Selling

In other Pediatrix Medical Group news, CEO James D. Swift sold 11,100 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $10.79, for a total value of $119,769.00. Following the completion of the sale, the chief executive officer now owns 170,001 shares in the company, valued at approximately $1,834,310.79. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Pediatrix Medical Group news, CEO James D. Swift sold 11,100 shares of the business’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $10.79, for a total value of $119,769.00. Following the transaction, the chief executive officer now owns 170,001 shares in the company, valued at approximately $1,834,310.79. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO C Marc Richards sold 32,562 shares of the stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $10.08, for a total transaction of $328,224.96. Following the sale, the chief financial officer now owns 192,785 shares of the company’s stock, valued at approximately $1,943,272.80. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 68,100 shares of company stock worth $701,889 in the last ninety days. 1.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Pediatrix Medical Group

Several hedge funds have recently made changes to their positions in MD. Vanguard Group Inc. raised its stake in Pediatrix Medical Group by 1.6% in the first quarter. Vanguard Group Inc. now owns 10,557,572 shares of the company’s stock worth $105,892,000 after buying an additional 164,333 shares in the last quarter. Rubric Capital Management LP raised its position in shares of Pediatrix Medical Group by 797.0% in the 2nd quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company’s stock worth $61,532,000 after acquiring an additional 7,241,400 shares in the last quarter. Boston Partners lifted its stake in shares of Pediatrix Medical Group by 34.0% in the 1st quarter. Boston Partners now owns 1,786,434 shares of the company’s stock valued at $17,702,000 after purchasing an additional 453,254 shares during the period. Dana Investment Advisors Inc. boosted its position in shares of Pediatrix Medical Group by 80.3% during the second quarter. Dana Investment Advisors Inc. now owns 1,023,136 shares of the company’s stock valued at $7,725,000 after purchasing an additional 455,785 shares in the last quarter. Finally, Brandes Investment Partners LP grew its stake in Pediatrix Medical Group by 12.8% in the second quarter. Brandes Investment Partners LP now owns 735,068 shares of the company’s stock worth $5,438,000 after purchasing an additional 83,588 shares during the period. 97.71% of the stock is owned by hedge funds and other institutional investors.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.